The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: Report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009-Reference-Cited by-同舟云学术

The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: Report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009

Published:2010-05 Issue:5 Volume:20 Page:355-362
ISSN:0960-8966
Container-title:Neuromuscular Disorders
language:en
Short-container-title:Neuromuscular Disorders

Author:

Muntoni F.

Publisher

Elsevier BV

Subject

Genetics (clinical),Neurology (clinical),Neurology,Pediatrics, Perinatology and Child Health

Reference23 articles.

1. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations;Aartsma-Rus;Hum Mut,2009

2. Bushby K, Finkel R, Birnkrant DJ et al. For the DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1; diagnosis, and pharmacological and psychosocial management and part 2: implementation of multidisciplinary care. Lancet Neurol 2009; Nov 27, e-Print.

3. 3.04 Assessment of StepWatchTM activity monitoring in a phase 2b study of Ataluren (PTC123TM) in nonsense mutation DMD/BMD;McDonald;Neuromus Dis,2009

4. 3.03 6-Minute walk test in Duchenne muscular dystrophy: longitudinal observations;McDonald;Neuromusc Dis,2009

5. Reproducibility and correlation of pre-treatment outcome measures in a phase 2b study of Ataluren (PTC123TM) in nonsense mutation Duchenne and Becker muscular dystrophy;Florence;Neuromuscul Disord,2009

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reliability and construct validity of the Duchenne Video Assessment;Muscle & Nerve;2021-06-16

2. Hereditary Neuromuscular Diseases. Part 3. Muscular Dystrophies: Pathogenesis, Diagnosis and Attempts of Trial Treatments;Russian neurological journal;2020-07-22

3. Preliminary Evidences of Safety and Efficacy of Flavonoids- and Omega 3-Based Compound for Muscular Dystrophies Treatment: A Randomized Double-Blind Placebo Controlled Pilot Clinical Trial;Frontiers in Neurology;2019-07-23

4. Biochemical Changes in Blood of Patients with Duchenne Muscular Dystrophy Treated with Granulocyte-Colony Stimulating Factor;BioMed Research International;2019-03-13

5. Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology;Journal of Neuromuscular Diseases;2019-01-30